The Manufacturers Life Insurance Company Invests $1.42 Million in Tyra Biosciences, Inc. $TYRA

The Manufacturers Life Insurance Company purchased a new position in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 44,327 shares of the company’s stock, valued at approximately $1,416,000.

A number of other institutional investors also recently made changes to their positions in the stock. Algert Global LLC lifted its position in shares of Tyra Biosciences by 27.2% in the second quarter. Algert Global LLC now owns 239,120 shares of the company’s stock valued at $7,637,000 after acquiring an additional 51,110 shares in the last quarter. BlackRock Inc. acquired a new position in Tyra Biosciences in the 2nd quarter valued at about $96,841,000. Deutsche Bank AG acquired a new position in Tyra Biosciences in the 2nd quarter valued at about $1,180,000. Bank of New York Mellon Corp purchased a new position in Tyra Biosciences in the 2nd quarter valued at about $3,313,000. Finally, State of Wyoming acquired a new stake in Tyra Biosciences during the second quarter worth approximately $76,000. 84.14% of the stock is owned by institutional investors and hedge funds.

Tyra Biosciences Price Performance

Tyra Biosciences stock opened at $24.86 on Friday. The stock’s 50-day moving average is $29.09 and its 200-day moving average is $32.05. The company has a market cap of $1.48 billion, a price-to-earnings ratio of -10.36 and a beta of 0.73. Tyra Biosciences, Inc. has a 12 month low of $11.70 and a 12 month high of $40.65.

Tyra Biosciences (NASDAQ:TYRA) last issued its earnings results on Tuesday, August 4th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). Research analysts anticipate that Tyra Biosciences, Inc. will post -2.74 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on TYRA shares. Jefferies Financial Group restated a “buy” rating and set a $42.00 price objective on shares of Tyra Biosciences in a report on Wednesday, August 5th. Wolfe Research initiated coverage on Tyra Biosciences in a report on Tuesday, May 19th. They issued a “peer perform” rating for the company. Bank of America upped their price objective on shares of Tyra Biosciences from $37.00 to $42.00 and gave the company a “buy” rating in a research note on Wednesday, June 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tyra Biosciences in a report on Friday, July 17th. Finally, JonesTrading assumed coverage on shares of Tyra Biosciences in a report on Wednesday, June 17th. They issued a “buy” rating and a $56.00 target price for the company. Twelve analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Tyra Biosciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $48.22.

Tyra Biosciences Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.